Compare LSE & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | ICCC |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 93.1M |
| IPO Year | 2023 | 1995 |
| Metric | LSE | ICCC |
|---|---|---|
| Price | $4.60 | $9.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.6K | ★ 11.3K |
| Earning Date | 10-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ $24.24 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $3.20 | $4.52 |
| 52 Week High | $6.98 | $12.10 |
| Indicator | LSE | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 43.74 |
| Support Level | $4.15 | $9.39 |
| Resistance Level | $5.09 | $10.16 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 50.32 | 48.57 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.